Citalopram updated on 07-01-2025

Ear, face and neck anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7351
R21513		 Wemakor, 2015 Ear, face and neck 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.56 [0.03;9.24] C 0/20   746/17,809 746 20
ref
S5884
R14738		 Ban (Controls unexposed, disease free), 2014 Ear, face, and neck malformations 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.00 [0.06;16.14] C 0/1,946   83/325,294 83 1,946
ref
S7179
R20208		 Colvin, 2011 Congenital anomalies of ear, face, and neck 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.18 [0.81;5.89] -/775   224/94,561 - 775
ref
Total 3 studies 1.76 [0.72;4.27] 829 2,741
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wemakor, 2015Wemakor, 2015 0.56[0.03; 9.24]7462010%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Ban (Controls unexposed, disease free), 2014Ban, 2014 1 1.00[0.06; 16.14]831,94610%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Colvin, 2011Colvin, 2011 2.18[0.81; 5.89]-77580%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.76[0.72; 4.27]8292,7410.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.00[0.78; 5.08]832,7210%NABan (Controls unexposed, disease free), 2014 Colvin, 2011 2 case control studiescase control studies 0.56[0.03; 9.24]74620 -NAWemakor, 2015 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.76[0.72; 4.27]8292,7410%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 3 Tags Adjustment   - No  - No 1.76[0.72; 4.27]8292,7410%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 3 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.56[0.03; 9.24]74620 -NAWemakor, 2015 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.00[0.78; 5.08]832,7210%NABan (Controls unexposed, disease free), 2014 Colvin, 2011 2 All studiesAll studies 1.76[0.72; 4.27]8292,7410%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.76[0.72; 4.27]1,0442,7410%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 30.510.01.0